TARDBP and amyotrophic lateral sclerosis: Given that HDAC6 co-aggregates with ubiquitin and α-synuclein in Parkinson’s disease (Kawaguchi et al., 2003), and elevated HDAC6 expression has been reported in FTLD patients with TDP-43 pathology (Odagiri et al., 2013), we wanted to examine the pattern of HDAC6 immunoreactivity in affected regions of the brain in both sporadic (sFTD/ALS) and c9FTD/ALS patients.